Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05715216 | EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer | PHASE2 | ACTIVE NOT_RECRUITING | 20 | — | — | Mar 24, 2023 | Feb 8, 2026 | May 16, 2025 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Etigilimab plus Nivolumab | EXPERIMENTAL | Participants will receive the study drugs on Days 1 and 15 of each study cycle,Cycle 1, Participants will receive the drugs on separate days (etigilimab on Day 1 and nivolumab on Day 2). Starting with Cycle 2, you will receive both drugs on Day 1 (separated by 2 hours). |
| Name | Type | Description |
|---|---|---|
| Nivolumab | DRUG | Given by IV (vein) |
| Etigilimab | DRUG | Given by IV (vein) |
Inclusion Criteria: Inclusion criteria will be assessed within 28 days of starting study treatment: 1. Ability to provide signed informed consent. 2. Age ≥ 18 years at time of study entry. 3. Willingness and ability to comply with the protocol for the duration of the study including undergoing tre...